IOV 5001
Alternative Names: Cytokine-tethered TIL therapy - Iovance Biotherapeutics; IOV-5001; Tethered IL-12 TIL cell therapy - Iovance BiotherapeuticsLatest Information Update: 26 May 2024
At a glance
- Originator Iovance Biotherapeutics
- Class Antineoplastics; Gene therapies; Immunotherapies; Tumour infiltrating lymphocyte therapies
- Mechanism of Action Immunologic cytotoxicity; Interleukin-12 expression stimulants; Lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer